Cargando…

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy

Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on immune cells to suppress anti-tumor immune responses. In the past decade, antibodies targeting PD-1/PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yao, Hong, Kai, Zhao, Yingchao, Xu, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321661/ https://www.ncbi.nlm.nih.gov/pubmed/37415977 http://dx.doi.org/10.3389/fimmu.2023.1228200

Ejemplares similares

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Elucidating the role of ubiquitination and deubiquitination in osteoarthritis progression
por: Zheng, Chenxiao, et al.
Publicado: (2023)

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
por: Qi, Yihang, et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Roles of Ubiquitination and Deubiquitination in Regulating Dendritic Cell Maturation and Function
por: Zhu, Bo, et al.
Publicado: (2020)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner
por: Ran, Xiang-Hong, et al.
Publicado: (2022)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study
por: Huang, Yu-Feng, et al.
Publicado: (2023)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Roles and therapeutic implications of m6A modification in cancer immunotherapy
por: Pan, Juan, et al.
Publicado: (2023)

Emerging roles of the gut microbiota in cancer immunotherapy
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling
por: Waad Sadiq, Zeinab, et al.
Publicado: (2023)

Emerging Role of Exosomes in Tuberculosis: From Immunity Regulations to Vaccine and Immunotherapy
por: Sun, Yin-Fu, et al.
Publicado: (2021)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

A novel immunogenic cell death–related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer
por: Dong, Bingqi, et al.
Publicado: (2023)

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells
por: Wang, Qianqian, et al.
Publicado: (2022)

Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients
por: Chen, Xinhua, et al.
Publicado: (2022)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Corrigendum: Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients
por: Chen, Xinhua, et al.
Publicado: (2023)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma
por: Jian, Yuli, et al.
Publicado: (2021)

Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases
por: Liang, Huayuan, et al.
Publicado: (2022)

Modified activities of macrophages’ deubiquitinating enzymes after Francisella infection
por: Vozandychova, Vera, et al.
Publicado: (2023)

The Deubiquitinating Enzyme Cylindromatosis Dampens CD8(+) T Cell Responses and Is a Critical Factor for Experimental Cerebral Malaria and Blood–Brain Barrier Damage
por: Schmid, Ursula, et al.
Publicado: (2017)

Advances in post-translational modifications of proteins and cancer immunotherapy
por: Li, Yanqing, et al.
Publicado: (2023)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity
por: Darling, Thayer K., et al.
Publicado: (2019)

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Regulation of Deubiquitinating Enzymes by Post-Translational Modifications
por: Das, Tanuza, et al.
Publicado: (2020)

Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients
por: Wang, Peng, et al.
Publicado: (2021)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma
por: Ding, Yixin, et al.
Publicado: (2023)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
por: Qiu, Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3rmk6km68d8oa9t00b9pten2c5